David E Fisher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5031828/publications.pdf

Version: 2024-02-01

195 papers	27,750 citations	7096 78 h-index	5829 161 g-index
202 all docs	202 docs citations	202 times ranked	29827 citing authors

#	Article	IF	Citations
1	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 2005, 436, 117-122.	27.8	1,329
2	Melanocyte biology and skin pigmentation. Nature, 2007, 445, 843-850.	27.8	1,048
3	MITF: master regulator of melanocyte development and melanoma oncogene. Trends in Molecular Medicine, 2006, 12, 406-414.	6.7	993
4	Mechanisms of Hair Graying: Incomplete Melanocyte Stem Cell Maintenance in the Niche. Science, 2005, 307, 720-724.	12.6	984
5	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research, 2013, 19, 1225-1231.	7.0	832
6	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 2017, 547, 413-418.	27.8	792
7	Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF. Cancer Cell, 2013, 23, 302-315.	16.8	689
8	Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability. Cell, 2002, 109, 707-718.	28.9	671
9	Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. Cancer Research, 2010, 70, 5213-5219.	0.9	659
10	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. Current Biology, 2005, 15, 249-254.	3.9	626
11	MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature, 1998, 391, 298-301.	27.8	588
12	Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation. Cell, 2007, 128, 853-864.	28.9	552
13	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Journal of Clinical Oncology, 2013, 31, 3182-3190.	1.6	530
14	Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 2015, 15, 747-756.	28.4	466
15	Microphthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes. Journal of Cell Biology, 1998, 142, 827-835.	5.2	456
16	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery, 2014, 4, 816-827.	9.4	448
17	Malignant melanoma: genetics and therapeutics in the genomic era. Genes and Development, 2006, 20, 2149-2182.	5.9	436
18	c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes and Development, 2000, 14, 301-312.	5.9	435

#	ARTICLE	IF	CITATIONS
19	Major Response to Imatinib Mesylate in <i>KIT</i>-Mutated Melanoma. Journal of Clinical Oncology, 2008, 26, 2046-2051.	1.6	430
20	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	30.5	417
21	Melanoma: from mutations to medicine. Genes and Development, 2012, 26, 1131-1155.	5.9	415
22	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103.	27.8	413
23	An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature, 2012, 491, 449-453.	27.8	406
24	Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity, 2019, 50, 1498-1512.e5.	14.3	406
25	Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell, 2004, 6, 565-576.	16.8	373
26	Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene, 2003, 22, 3035-3041.	5.9	337
27	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science, 2014, 346, 945-949.	12.6	328
28	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	16.8	327
29	From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 2012, 12, 349-361.	28.4	323
30	Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature, 2006, 443, 340-344.	27.8	302
31	High-throughput mapping of the chromatin structure of human promoters. Nature Biotechnology, 2007, 25, 244-248.	17.5	300
32	TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition. Cancer Research, 2007, 67, 919-929.	0.9	275
33	Î²-Cateninâ€“induced melanoma growth requires the downstream target <i>Microphthalmia</i>-associated transcription factor. Journal of Cell Biology, 2002, 158, 1079-1087.	5.2	268
34	MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma. American Journal of Pathology, 2003, 163, 333-343.	3.8	266
35	Skin Î²-Endorphin Mediates Addiction to UV Light. Cell, 2014, 157, 1527-1534.	28.9	254
36	Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma. Molecular Cell, 2010, 40, 841-849.	9.7	246

#	ARTICLE	IF	CITATIONS
37	Cloning of an <i>Alpha-TFEB</i> fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6051-6056.	7.1	238
38	Microphthalmia Transcription Factor. American Journal of Pathology, 1999, 155, 731-738.	3.8	233
39	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654.	3.4	226
40	Label-free DNA imaging in vivo with stimulated Raman scattering microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11624-11629.	7.1	225
41	atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nature Genetics, 1997, 16, 397-401.	21.4	216
42	Î±-Melanocyte-stimulating Hormone Signaling Regulates Expression of microphthalmia, a Gene Deficient in Waardenburg Syndrome. Journal of Biological Chemistry, 1998, 273, 33042-33047.	3.4	202
43	Pathways and therapeutic targets in melanoma. Oncotarget, 2014, 5, 1701-1752.	1.8	202
44	<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4321-4326.	7.1	200
45	Key Roles for Transforming Growth Factor Î² in Melanocyte Stem Cell Maintenance. Cell Stem Cell, 2010, 6, 130-140.	11.1	197
46	The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Laboratory Investigation, 2017, 97, 649-656.	3.7	197
47	Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology, 2021, 141, 23-31.	0.7	193
48	Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma. Cancer Research, 2004, 64, 509-516.	0.9	191
49	Pre-bending of a promoter sequence enhances affinity for the TATA-binding factor. Nature, 1995, 373, 724-727.	27.8	189
50	Lineage-specific Signaling in Melanocytes. Journal of Biological Chemistry, 1998, 273, 17983-17986.	3.4	174
51	Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers. Cancer Cell, 2006, 9, 473-484.	16.8	172
52	Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells. Nature, 2020, 577, 676-681.	27.8	158
53	Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Human Molecular Genetics, 2000, 9, 125-132.	2.9	150
54	Linkage of M-CSF Signaling to Mitf, TFE3, and the Osteoclast Defect in Mitfmi/mi Mice. Molecular Cell, 2001, 8, 749-758.	9.7	145

#	ARTICLE	IF	CITATIONS
55	c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage. Journal of Biological Chemistry, 2006, 281, 10365-10373.	3.4	145
56	Indoor Tanning â€" Science, Behavior, and Policy. New England Journal of Medicine, 2010, 363, 901-903.	27.0	130
57	Sumoylation of MITF and Its Related Family Members TFE3 and TFEB. Journal of Biological Chemistry, 2005, 280, 146-155.	3.4	128
58	UV Signaling Pathways within the Skin. Journal of Investigative Dermatology, 2014, 134, 2080-2085.	0.7	128
59	Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma. Clinical Cancer Research, 2008, 14, 7726-7732.	7.0	126
60	Biology and Clinical Relevance of the Micropthalmia Family of Transcription Factors in Human Cancer. Journal of Clinical Oncology, 2011, 29, 3474-3482.	1.6	124
61	Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer, 2017, 123, 2143-2153.	4.1	119
62	Lineage-Specific Transcriptional Regulation of DICER by MITF in Melanocytes. Cell, 2010, 141, 994-1005.	28.9	113
63	The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Archives of Biochemistry and Biophysics, 2014, 563, 28-34.	3.0	109
64	An Oncogenic Role for <i>ETV1</i> in Melanoma. Cancer Research, 2010, 70, 2075-2084.	0.9	107
65	A new era: melanoma genetics and therapeutics. Journal of Pathology, 2011, 223, 242-251.	4.5	107
66	Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell and Melanoma Research, 2008, 21, 457-463.	3.3	104
67	How Sunlight Causes Melanoma. Current Oncology Reports, 2010, 12, 319-326.	4.0	104
68	Hypoxia-induced transcriptional repression of the melanoma-associated oncogene <i>MITF</i>. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E924-33.	7.1	101
69	Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma. Cancer Research, 2010, 70, 639-645.	0.9	100
70	Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends in Endocrinology and Metabolism, 2018, 29, 723-735.	7.1	92
71	Isolation and Molecular Characterization of Circulating Melanoma Cells. Cell Reports, 2014, 7, 645-653.	6.4	91
72	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6157-E6165.	7.1	90

#	ARTICLE	IF	CITATIONS
73	Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3. Journal of Experimental Medicine, 1998, 187, 775-785.	8.5	88
74	UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell and Melanoma Research, 2008, 21, 509-516.	3.3	88
75	Identification of Aim-1 as the underwhiteMouse Mutant and Its Transcriptional Regulation by MITF. Journal of Biological Chemistry, 2002, 277, 402-406.	3.4	87
76	Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene, 2005, 347, 73-82.	2.2	86
77	Regulation of MITF stability by the USP13 deubiquitinase. Nature Communications, 2011, 2, 414.	12.8	86
78	PGC-1 Coactivators Regulate MITF and the Tanning Response. Molecular Cell, 2013, 49, 145-157.	9.7	84
79	<scp>MITF</scp> and <scp>UV</scp> responses in skin: From pigmentation to addiction. Pigment Cell and Melanoma Research, 2019, 32, 224-236.	3.3	84
80	Sensorineural Deafness and Pigmentation Genes. Neuron, 2001, 30, 15-18.	8.1	83
81	A Tissue-restricted cAMP Transcriptional Response. Journal of Biological Chemistry, 2003, 278, 45224-45230.	3.4	83
82	Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. Clinical Cancer Research, 2014, 20, 2257-2263.	7.0	79
83	Epistatic connections between microphthalmiaâ€associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB Journal, 2008, 22, 1155-1168.	0.5	78
84	A Melanoma Molecular Disease Model. PLoS ONE, 2011, 6, e18257.	2.5	77
85	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
86	How does pheomelanin synthesis contribute to melanomagenesis?. BioEssays, 2013, 35, 672-676.	2.5	75
87	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD+ Depletionâ€“Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.9	74
88	Skin pigmentation and its control: From ultraviolet radiation to stem cells. Experimental Dermatology, 2021, 30, 560-571.	2.9	74
89	Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Current Opinion in Oncology, 2009, 21, 144-149.	2.4	72
90	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNÎ³ pathways. Nature Reviews Clinical Oncology, 2019, 16, 549-562.	27.6	72

#	ARTICLE	IF	CITATIONS
91	Control of melanocyte differentiation by a MITFâ€“PDE4D3 homeostatic circuit. Genes and Development, 2010, 24, 2276-2281.	5.9	68
92	Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell and Melanoma Research, 2010, 23, 741-745.	3.3	67
93	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncology, 2015, 1, 1340.	7.1	63
94	A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Reports, 2017, 19, 2177-2184.	6.4	59
95	Extensive apoptosis in ductal carcinoma in situ of the breast. , 1996, 77, 1831-1835.		54
96	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine, 2021, 13, .	12.4	54
97	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.0	53
98	A phase I trial of panobinostat (<scp>LBH</scp>589) in patients with metastatic melanoma. Cancer Medicine, 2016, 5, 3041-3050.	2.8	51
99	Diffuse large cell lymphoma with discordant bone marrow histology. Clinical features and biological implications. Cancer, 1989, 64, 1879-1887.	4.1	48
100	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.7	46
101	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157.	12.8	46
102	YY1 Regulates Melanocyte Development and Function by Cooperating with MITF. PLoS Genetics, 2012, 8, e1002688.	3.5	45
103	ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Molecular Cancer Research, 2015, 13, 1206-1217.	3.4	44
104	Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. Cancer Discovery, 2020, 10, 980-997.	9.4	44
105	Metastatic melanoma and immunotherapy. Clinical Immunology, 2016, 172, 105-110.	3.2	43
106	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. PLoS ONE, 2014, 9, e101286.	2.5	42
107	FOXD3 Regulates VISTA Expression in Melanoma. Cell Reports, 2020, 30, 510-524.e6.	6.4	42
108	Dual roles of lineage restricted transcription factors. Transcription, 2011, 2, 19-22.	3.1	41

#	ARTICLE	IF	CITATIONS
109	Melanocyte stem cells as potential therapeutics in skin disorders. Expert Opinion on Biological Therapy, 2014, 14, 1569-1579.	3.1	41
110	The melanomaâ€linked â€œredheadâ€•<i>MC1R</i> influences dopaminergic neuron survival. Annals of Neurology, 2017, 81, 395-406.	5.3	41
111	Biology of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 29-56.	2.2	40
112	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE, 2015, 10, e0140310.	2.5	39
113	ROCK inhibitor enhances the growth and migration of BRAFâ€mutant skin melanoma cells. Cancer Science, 2018, 109, 3428-3437.	3.9	36
114	Topical treatment strategies to manipulate human skin pigmentation. Advanced Drug Delivery Reviews, 2020, 153, 65-71.	13.7	35
115	NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. Cell, 2021, 184, 4268-4283.e20.	28.9	35
116	New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances. Clinical Cancer Research, 2011, 17, 4922-4928.	7.0	34
117	Biologic Activity of Autologous, Granulocyteâ€“Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	7.0	34
118	Understanding the Biology of Melanoma and Therapeutic Implications. Hematology/Oncology Clinics of North America, 2014, 28, 437-453.	2.2	33
119	Transcription Factor Tfe3 Directly Regulates Pgcâ€1alpha in Muscle. Journal of Cellular Physiology, 2015, 230, 2330-2336.	4.1	33
120	In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. Scientific Reports, 2016, 6, 37986.	3.3	33
121	Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. Journal of Investigative Dermatology, 2017, 137, 2523-2531.	0.7	32
122	SOX10 Regulates Melanoma Immunogenicity through an IRF4â€“IRF1 Axis. Cancer Research, 2021, 81, 6131-6141.	0.9	31
123	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 75-102.	22.4	30
124	Central role for cAMP signaling in pigmentation and UV resistance. Cell Cycle, 2011, 10, 8-9.	2.6	29
125	MSX1-Induced Neural Crest-Like Reprogramming Promotes MelanomaÂProgression. Journal of Investigative Dermatology, 2018, 138, 141-149.	0.7	29
126	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 2019, 125, 18-44.	4.1	29

#	ARTICLE	IF	CITATIONS
127	Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. Journal of Experimental Medicine, 2020, 217, .	8.5	28
128	Microphthalmia: A Signal Responsive Transcriptional Regulator in Development. Pigment Cell & Melanoma Research, 2000, 13, 145-149.	3.6	25
129	Notch and Melanocytes: Diverse Outcomes from a Single Signal. Journal of Investigative Dermatology, 2008, 128, 2571-2574.	0.7	25
130	Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans. JAMA Dermatology, 2016, 152, 751.	4.1	24
131	Specification and loss of melanocyte stem cells. Seminars in Cell and Developmental Biology, 2009, 20, 111-116.	5.0	23
132	Transcriptional Regulation in Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 447-465.	2.2	21
133	Disproportionate Burden of Melanoma Mortality in Young US Men. JAMA Dermatology, 2013, 149, 903.	4.1	21
134	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Medicine, 2016, 13, e1002196.	8.4	21
135	Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion. Developmental Biology, 2019, 449, 107-114.	2.0	19
136	Chest wall recurrence of ductal carcinoma in situ of the breast after mastectomy. Cancer, 1993, 71, 3025-3028.	4.1	18
137	Myosin-Va Contributes to Manifestation of Malignant-Related Properties in Melanoma Cells. Journal of Investigative Dermatology, 2013, 133, 2809-2812.	0.7	17
138	A Novel Role for Microphthalmia-Associated Transcription Factorâ€“Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. American Journal of Pathology, 2015, 185, 252-265.	3.8	17
139	Tfe3 and Tfeb Transcriptionally Regulate Peroxisome Proliferator-Activated Receptor Î³2 Expression in Adipocytes and Mediate Adiponectin and Glucose Levels in Mice. Molecular and Cellular Biology, 2017, 37, .	2.3	17
140	The lncRNA RMEL3 protects immortalized cells from serum withdrawalâ€induced growth arrest and promotes melanoma cell proliferation and tumor growth. Pigment Cell and Melanoma Research, 2019, 32, 303-314.	3.3	17
141	Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair. Oncogene, 2019, 38, 3616-3635.	5.9	17
142	Non-Euclidean phasor analysis for quantification of oxidative stress in ex vivo human skin exposed to sun filters using fluorescence lifetime imaging microscopy. Journal of Biomedical Optics, 2017, 22, 1.	2.6	17
143	Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Science Advances, 2021, 7, .	10.3	16
144	FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy. International Journal of Cardiology, 2015, 195, 85-94.	1.7	15

#	ARTICLE	IF	CITATIONS
145	Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS ONE, 2016, 11, e0155217.	2.5	14
146	Developing melanoma therapeutics: overview and update. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 257-271.	6.6	13
147	Highâ€throughput, highâ€content screening for novel pigmentation regulators using a keratinocyte/melanocyte coâ€culture system. Experimental Dermatology, 2014, 23, 125-129.	2.9	13
148	Local genomic features predict the distinct and overlapping binding patterns of the bHLHâ€Zip family oncoproteins MITF and MYCâ€MAX. Pigment Cell and Melanoma Research, 2019, 32, 500-509.	3.3	13
149	Topical therapy for regression and melanoma prevention of congenital giant nevi. Cell, 2022, 185, 2071-2085.e12.	28.9	13
150	Stressâ€associated ectopic differentiation of melanocyte stem cells and ORS amelanotic melanocytes in an ex vivo human hair follicle model. Experimental Dermatology, 2021, 30, 578-587.	2.9	12
151	The Impact of MITF on Melanoma Development: News from Bench and Bedside. Journal of Investigative Dermatology, 2014, 134, 16-17.	0.7	11
152	CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. Cell Chemical Biology, 2021, 28, 1407-1419.e6.	5.2	11
153	Monitoring Repair of UV-Induced 6-4-Photoproducts with a Purified DDB2 Protein Complex. PLoS ONE, 2014, 9, e85896.	2.5	11
154	Targeting melanoma by small molecules: challenges ahead. Pigment Cell and Melanoma Research, 2013, 26, 464-469.	3.3	10
155	Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death. Molecular Cancer Therapeutics, 2020, 19, 627-636.	4.1	10
156	MYO5A Gene Is a Target of MITF inÂMelanocytes. Journal of Investigative Dermatology, 2017, 137, 985-989.	0.7	9
157	Hair repigmentation associated with the use of brentuximab. JAAD Case Reports, 2017, 3, 563-565.	0.8	9
158	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clinical Cancer Research, 2017, 23, 4680-4692.	7.0	8
159	G9a: An Emerging Epigenetic Target for Melanoma Therapy. Epigenomes, 2021, 5, 23.	1.8	8
160	Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2022, 17, 16.	10.8	8
161	Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. Journal of the American Academy of Dermatology, 2018, 79, 230-237.	1.2	7
162	A ROCK inhibitor promotes keratinocyte survival and paracrine secretion, enhancing establishment of primary human melanocytes and melanocyteâ€“keratinocyte coâ€cultures. Pigment Cell and Melanoma Research, 2020, 33, 16-29.	3.3	7

#	ARTICLE	IF	CITATIONS
163	Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study. Journal of General Internal Medicine, 2020, 35, 2545-2552.	2.6	7
164	Reduced MC4R signaling alters nociceptive thresholds associated with red hair. Science Advances, 2021, 7, .	10.3	7
165	Turning p53 on or off: either way may treat cancer. Drug Resistance Updates, 2000, 3, 77-79.	14.4	6
166	UV and melanoma: the TP53 link. Cell Research, 2014, 24, 1157-1158.	12.0	6
167	Bioinformatic Analysis of Gene Expression for Melanoma Treatment. Journal of Investigative Dermatology, 2016, 136, 2342-2344.	0.7	6
168	Melanocortin 1 receptor is dispensable for acute stress induced hair graying in mice. Experimental Dermatology, 2021, 30, 572-577.	2.9	6
169	Targeting the (Un)differentiated State of Cancer. Cancer Cell, 2018, 33, 793-795.	16.8	5
170	Tanning as a substance abuse. Communicative and Integrative Biology, 2014, 7, e971579.	1.4	4
171	Pathways in melanoma development. Italian Journal of Dermatology and Venereology, 2018, 153, 68-76.	0.2	4
172	Biology of Melanocytes and Primary Melanoma. , 2020, , 3-40.		4
173	Metabolic Vulnerability in Melanoma: A ME2 (Me Too) Story. Journal of Investigative Dermatology, 2015, 135, 657-659.	0.7	3
174	Microphthalmiaâ€associated transcription factor phosphorylation: Cross talk between GSK3 and MAPK signaling. Pigment Cell and Melanoma Research, 2019, 32, 345-347.	3.3	3
175	Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer. International Journal of Oncology Research, 2021, 4, .	0.1	2
176	Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer, 1996, 77, 1831-1835.	4.1	2
177	Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma. Journal of Investigative Dermatology, 2022, 142, 1004-1006.	0.7	2
178	Authors' Reply. American Journal of Pathology, 2015, 185, 2070.	3.8	1
179	Negative Regulation of Skin Pigmentation in Three-Dimensional Reconstructs by Adipose-Derived Mesenchymal Cells. Journal of Investigative Dermatology, 2017, 137, 2464-2466.	0.7	1
180	miRNA-211 stops the clock. Non-coding RNA Investigation, 2018, 2, 25-25.	0.6	1

#	Article	IF	Citations
181	Hormones and Hormone Precursors of the Skin. , 2020, , 531-556.		1
182	The Melanocyte Lineage Factor miR-211 Promotes BRAFV600E Inhibitor Resistance. Journal of Investigative Dermatology, 2021, 141, 250-252.	0.7	1
183	Transcriptional Regulation in Melanoma. , 2011, , 79-103.		1
184	Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.. Journal of Clinical Oncology, 2013, 31, 9080-9080.	1.6	1
185	The Biology of Pigmentation. , 2018, , 1-30.		1
186	Scientific and social controversies regarding UV and pigmentation: the beneficial effects of UV irradiance outweighs the risks - a reply. Pigment Cell and Melanoma Research, 2009, 22, 139-139.	3.3	0
187	Preface. Hematology/Oncology Clinics of North America, 2009, 23, xiii-xiv.	2.2	0
188	Shin-Ichi Nishikawa MD, PhD. Pigment Cell and Melanoma Research, 2010, 23, 683-683.	3.3	0
189	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. Neuro-Oncology, 2018, 20, vi106-vi107.	1.2	0
190	The Biology of Pigmentation. , 2019, , 21-50.		0
191	Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Surveyâ€Based Crossâ€Sectional Cohort Study. Pediatric Dermatology, 2019, 36, 882-886.	0.9	0
192	MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma. Journal of Investigative Dermatology, 2021, 141, 2782-2784.	0.7	0
193	Transcriptional Regulation in Melanoma. , 2017, , 95-117.		0
194	Biology of Melanocytes and Primary Melanoma. , 2019, , 1-38.		0
195	Commentary on NNT Mediates Redox-Dependent Pigmentation a UVB-And MITF-Independent Mechanism.. Journal of Cell Science & Therapy, 2021, 12, .	0.3	0